The Why
While women account for roughly 50% of the world’s population, their unique health concerns have traditionally received a much smaller fraction of research focus. That’s changing as dedicated researchers are making strides in treating many gender-specific conditions.
Results
We’re a proud partner to leading pharmaceutical companies, through women’s health clinical trials, in their investigation of new drug therapies devoted to improving gender-specific care.
- Elagolix sodium for pain associated with endometriosis approved July 2018
- Vibegron for over active bladder approved December 2020